In the final 5-year open-label extension of the phase 3 POISE trial (193 patients with PBC and inadequate response or intolerance to UDCA), obeticholic acid showed sustained efficacy: primary endpoint response 63% at month 72. Pruritus occurred in 70%.
RCTn = 193
Bowlus et al. Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension